v3.26.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning balance (in shares) at Dec. 31, 2024     8,410,000          
Beginning balance at Dec. 31, 2024 $ 29,317 $ 29,571 $ 8 $ 578,418 $ (81) $ (548,066) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,724) (4,724)       (4,724)    
Share-based compensation (in shares)     151,000          
Share-based compensation 286 286   286        
Net proceeds from issuances of common stock (in shares)     56,000          
Net proceeds from issuances of common stock 212 212 $ 1 211        
Proceeds from option exercises (in shares)     4,000          
Proceeds from option exercises 8 8   8        
Unrealized loss on marketable securities (2) (2)     (2)      
Foreign currency translation adjustment 5 5     5      
Ending balance (in shares) at Mar. 31, 2025     8,621,000          
Ending balance at Mar. 31, 2025 $ 25,102 25,356 $ 9 578,923 (78) (552,790) (708) (254)
Beginning balance (in shares) at Dec. 31, 2025 8,833,875   8,835,000          
Beginning balance at Dec. 31, 2025 $ 14,601 14,855 $ 9 580,243 (37) (564,652) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (4,489) (4,489)       (4,489)    
Share-based compensation (in shares)     119,000          
Share-based compensation $ 204 204   204        
Proceeds from option exercises (in shares) 79,295   79,000          
Proceeds from option exercises $ 124 124   124        
Proceeds from warrant exercise (in shares) 75,000              
Proceeds from warrant exercise $ 216              
Foreign currency translation adjustment $ 16 16     16      
Ending balance (in shares) at Mar. 31, 2026 9,107,291   9,108,000          
Ending balance at Mar. 31, 2026 $ 10,672 $ 10,926 $ 9 $ 580,787 $ (21) $ (569,141) $ (708) $ (254)